The project grant award K08AI187736, totaling $194,740, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research conducted by Dr. Daniel Shin at Boston Children's Hospital to study the development of lung-resident self-antigen-specific regulatory T cells (Tregs) following acute lung injury. The key goals are to characterize the population dynamics, phenotype, and function of these "experienced" self-antigen-specific Tregs in promoting long-term tolerance to prevent recurrent lung injury and autoimmunity. The research utilizes an improved mouse model, novel barcoded tetramers, and a parabiosis approach to investigate these mechanisms. The award provides funding from March 1, 2025 through February 28, 2030 to support Dr. Shin's career development and transition to becoming an independent NIH-funded investigator with expertise in peripheral tolerance and tissue-resident Treg biology.